Nonalcoholic fatty liver disease is prevalent in women with prior gestational diabetes mellitus and independently associated with insulin resistance and waist circumference

Diabetes Care

Volumn 40, Issue 1, 2017, Pages 109-116

  Foghsgaard, Signe ^a,b,c   Andreasen, Camilla ^a   Vedtofte, Louise ^a   Andersen, Emilie S ^a   Bahne, Emilie ^a   Strandberg, Charlotte ^a   Buhl, Thora ^a   Holst, Jens J ^b   Svare, Jens A ^a   Clausen, Tine D ^a   Mathiesen, Elisabeth R ^a   Damm, Peter ^a   Gluud, Lise L ^a   Knop, Filip K ^a,b   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; INTRAPERITONEAL FAT; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PREVALENCE; RISK ASSESSMENT; WAIST CIRCUMFERENCE; COMPLICATION; DIAGNOSTIC IMAGING; GLUCOSE TOLERANCE TEST; INTRAABDOMINAL FAT; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PREGNANCY; PUERPERIUM; RISK FACTOR;

ADULT; DIABETES, GESTATIONAL; FEMALE; GLUCAGON; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTPARTUM PERIOD; PREGNANCY; PREVALENCE; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 85008235593     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1017     Document Type: Article

References (41)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231
2. Blachier M, Leleu H, Peck-RadosavljevicM, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 2013;58:593-608
3. SmithBW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456-465
4. Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960
5. Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014;20:8377-8392
6. Stefan N, Häring H-U. The metabolically benign and malignant fatty liver. Diabetes 2011; 60:2011-2017
7. Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: A diabetologist's perspective. Endocrine 2014; 45:344-353
8. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-121
9. Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsbøll T. Effects of glucagon-like peptide-1 on glucagon secretion in patients with nonalcoholic fatty liver disease. J Hepatol 2016;64: 908-915
10. Kobyliak N, Abenavoli L. The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014;9:159-169
11. Buckley BS, Harreiter J, DammP, et al.; DALI Core Investigator Group. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med 2012;29:844-854
12. Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after gestational diabetes: A long-term follow-up in a Danish population. Diabetes Care 2004;27:1194-1199
13. Kitzmiller JL, Dang-Kilduff L, Taslimi MM. Gestational diabetes after delivery. Short-term management and long-term risks. Diabetes Care 2007;30(Suppl. 2):S225-S235
14. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 2002;25: 1862-1868
15. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005;90:4004-4010
16. Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia 2011;54:641-647
17. Foghsgaard S, Vedtofte L, Mathiesen ER, et al. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance inwomen with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open 2013;3: e003834
18. Sasso M, Miette V, Sandrin L, BeaugrandM. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012;36:13-20
19. Kaul S, Rothney MP, Peters DM, et al. Dualenergy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring) 2012;20: 1313-1318
20. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation [Internet], 2006. Geneva, Switzerland, World Health Organization. Available from http://www.who.int/diabetes/publications/Definition%20 and%20diagnosis%20of%20diabetes-new.pdf. Accessed 1 March 2016
21. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
22. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192
23. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979;28:1086-1096
24. Alberti KGMM, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
25. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33
26. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993;88:791-804
27. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011;60:3103-3109
28. Wewer Albrechtsen NJ, Bak MJ, Hartmann B, et al. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect 2015;4:50-57
29. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-661
30. Ostoft SH, Bagger JI, Hansen T, et al. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturityonset diabetes of the youngdtype 2 and type 3. Diabetes 2014;63:2838-2844
31. Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational diabetes mellitus is strongly associated with nonalcoholic fatty liver disease. Am J Gastroenterol 2016;111:658-664
32. Suppli MP, Lund A, Bagger JI, Vilsbøll T, Knop FK. Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. Med Hypotheses 2016;86:100-103
33. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, et al. Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with nonalcoholic fatty liver disease. PLoS One 2014;9: e87488
34. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: The British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009;32:741-750
35. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137:865-872
36. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-491
37. De Souza LR, Berger H, Retnakaran R, et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol 2016; 111:665-670
38. Yki-Järvinen K. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009;20:477-483
39. DeFronzo RA, Abdul-Ghani MA. Preservation of b-cell function: The key to diabetes prevention. J Clin Endocrinol Metab 2011;96: 2354-2366
40. Carbone LJ, Angus PW, Yeomans ND. Incretinbased therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31:23-31
41. ArmstrongMJ, Hull D, Guo K, et al. Glucagonlike peptide 1 decreases lipotoxicity in nonalcoholic steatohepatitis. J Hepatol 2016;64: 399-408